Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

Endocrine Therapy Alone Shows Benefit for Some with Early Breast Cancer

LISA SCHULMEISTER, MN, RN, FAAN
Monday, June 04, 2018
Game-changing data published in the New England Journal of Medicine and presented during the 2018 ASCO Annual Meeting indicates that many women with hormone-receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer would see no significant benefit to having chemotherapy in addition to endocrine therapy.

Standard treatment of this subgroup of women with breast cancer has traditionally used a recurrence score (based on a 21-gene breast cancer assay) to determine if a woman should receive endocrine therapy alone or endocrine therapy plus chemotherapy. Women at low risk of recurrence (<10) typically received endocrine therapy alone while those at high risk (>25) received the combination therapy. The problem was that there was uncertainty about how women with a midrange recurrence score of 11-25 should be treated. 

A large group of researchers led by Joseph Sparano, MD, from Albert Einstein College of Medicine in Bronx, NY, conducted a prospective trial called TAILORx, involving 9719 women with HR–positive, HER2–negative, axillary node–negative breast cancer. In this group, 6711 (69%) with a midrange recurrence score of 11-25 were randomly assigned to receive either endocrine therapy alone or endocrine therapy plus chemotherapy.

At 9 years, the endocrine-therapy group and the endocrine therapy plus chemotherapy group had similar rates of invasive disease–free survival (DFS; 83.3% vs. 84.3%, respectively), freedom from disease recurrence at a distant site (94.5% vs. 95%, respectively) or at a distant or local–regional site (92.2% vs. 92.9%, respectively), and overall survival (93.9% vs. 93.8%, respectively). The chemotherapy benefit for invasive DFS varied with the combination of recurrence score and age, with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16-25.


 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
 
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
 
 
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.